Neratinib, fulvestrant, trastuzumab combo aids metastatic breast cancer
For patients with hormone receptor (HR)-positive HER2-mutant metastatic breast cancer (MBC) with progression on cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy, neratinib + fulvestrant + trastuzumab (N + F + T) is ...
Nov 29, 2023
0
0